Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1
DOI: 10.1016/j.pvr.2018.08.002
Alfred Saah ,
Beatriz Grinsztejn ,
Catherine Godfrey ,
Cynthia Firnhaber ,
Erna Milunka Kojic ,
Jennifer Y. Webster-Cyriaque ,
Judith A. Aberg ,
Michelle S. Cespedes ,
Minhee Kang ,
Reena Masih ,
Susan Cu-Uvin ,
Triin Umbleja Keywords: ACTG , AIDS Clinical Trials Group , AMC , AIDS Malignancy Consortium , ART , antiretroviral therapy , CI , confidence interval , CIN , cervical intraepithelial neoplasia , DNA , deoxyribonucleic acid , FDA , Food and Drug Administration , GMT , geometric mean titers , HIV , human immunodeficiency virus , HPV , human papillomavirus , mMU , milliMerck units , NA-ACCORD , North American AIDS Cohort Collaboration on Research and Design , nHPV , nonavalent human papillomavirus vaccine , NIAID , National Institute of Allergy and Infectious Diseases , NIDCR , National Institute of Dental and Craniofacial Research , NIH , National Institutes of Health , PCR , polymerase chain reaction , qHPV , quadrivalent human papillomavirus vaccine , VIN , vaginal intraepithelial neoplasia , WIHS , Women's Interagency HIV Study (WIHS) HPV , HIV , Anogenital , Quadrivalent HPV vaccine , Women , Immunogenicity
Abstract:
People living with HIV have increased Human Papillomavirus (HPV) related lesions and malignancies. We describe HPV DNA recovered from the cervix and anal canal, explore the effect of vaccination on HPV detection, and examine the durability of vaccine titers in women living with HIV-1 who were vaccinated with the quadrivalent HPV vaccine
Full-Text
